Succinate accumulation during ischaemia drives reactive oxygen species production at Complex I upon reperfusion, presenting a novel therapeutic target for myocardial ischaemia/reperfusion injury.
Myocardial ischaemia/reperfusion (IR) injury is a major cause of death worldwide and remains a disease for which current clinical therapies are strikingly deficient. While the production of mitochondrial reactive oxygen species (ROS) is a critical driver of tissue damage upon reperfusion, the precise mechanisms underlying ROS production have remained elusive. More recently, it has been demonstrated that a specific metabolic mechanism occurs during ischaemia that underlies elevated ROS at reperfusion, suggesting a unifying model as to why so many different compounds have been found to be cardioprotective against IR injury. This review will discuss the role of the citric acid cycle intermediate succinate in IR pathology focusing on the mechanism by which this metabolite accumulates during ischaemia and how it can drive ROS production at Complex I via reverse electron transport. We will then examine the potential for manipulating succinate accumulation and metabolism during IR injury in order to protect the heart against IR damage and discuss targets for novel therapeutics designed to reduce reperfusion injury in patients.
Pell et al. (Wed,) conducted a review in Myocardial ischaemia/reperfusion (IR) injury. Manipulating succinate accumulation and metabolism was evaluated. Succinate accumulation during ischaemia drives reactive oxygen species production at Complex I upon reperfusion, presenting a novel therapeutic target for myocardial ischaemia/reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: